United Therapeutics (UTHR) director sells 45 shares under 10b5-1 plan

Rhea-AI Filing Summary

United Therapeutics director Jan Malcolm reported an open-market sale of company stock. On March 17, 2026, Malcolm sold 45 shares of Common Stock at an average price of $533.51 per share, and now directly holds 125 shares. The sale was executed under a pre-arranged Rule 10b5-1 trading plan that Malcolm entered into on September 11, 2025, indicating the transaction was scheduled in advance rather than timed discretionarily.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

MALCOLM JAN

(Last) (First) (Middle)

C/O UNITED THERAPEUTICS CORPORATION

1000 SPRING STREET

(Street)

SILVER SPRING MD 20910

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
UNITED THERAPEUTICS Corp [ UTHR ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
03/17/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	03/17/2026		S(1)		45	D	$533.51	125	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. This sale of shares was pursuant to a Rule 10b5-1 trading plan entered into by the reporting person on September 11, 2025.

Remarks:

	/s/ John S. Hess, Jr. under Power of Attorney	03/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did UNITED THERAPEUTICS (UTHR) director Jan Malcolm report?

Director Jan Malcolm reported an open-market sale of 45 shares of UNITED THERAPEUTICS Common Stock. The shares were sold at an average price of $533.51 each, and the transaction was disclosed in a Form 4 insider trading report filed with regulators.

At what price did Jan Malcolm sell UNITED THERAPEUTICS (UTHR) shares?

Jan Malcolm sold 45 UNITED THERAPEUTICS Common Stock shares at an average price of $533.51 per share. This reflects an open-market sale, as classified in the filing, and helps investors understand the dollar value and pricing of the reported insider transaction.

How many UNITED THERAPEUTICS (UTHR) shares does Jan Malcolm hold after the sale?

Following the reported sale, Jan Malcolm directly holds 125 shares of UNITED THERAPEUTICS Common Stock. This post-transaction ownership figure comes from the Form 4 and shows that only a limited portion of Malcolm’s reported direct holdings was sold in this transaction.

Was Jan Malcolm’s UNITED THERAPEUTICS (UTHR) stock sale under a Rule 10b5-1 plan?

Yes. The filing states that the 45-share sale was made under a Rule 10b5-1 trading plan entered into on September 11, 2025. Such pre-arranged plans schedule trades in advance, reducing the significance of timing decisions around individual transactions.

What type of transaction code was used in Jan Malcolm’s UNITED THERAPEUTICS (UTHR) Form 4?

The Form 4 lists transaction code “S,” indicating a sale of non-derivative Common Stock. The filing describes it as an open-market or private sale, confirming this was a straightforward disposition of shares rather than an option exercise, gift, or tax-withholding event.

Does Jan Malcolm’s UNITED THERAPEUTICS (UTHR) Form 4 show any derivative security activity?

No derivative transactions are reported in this Form 4. The derivative section is empty, indicating there were no option exercises, warrant conversions, or similar derivative movements disclosed alongside the 45-share open-market sale of Common Stock in this filing.